Back to Newsroom

Axovant Sciences Announces Preliminary Results from Interim Analysis of Phase 2 Study Testing Investigational Drug Nelotanserin in Lewy Body Dementia Patients

— Beneficial treatment effect observed on the pre-specified primary endpoint of Unified Parkinson’s Disease Rating Scale (UPDRS) Parts II + III– Axovant plans to expand study recruitment to further explore UPDRS findings and expects final results in mid-2017– Axovant expects to initiate Phase 3 program in the second half of 2017

BASEL, Switzerland, Feb. 13, 2017 /PRNewswire/ — Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced preliminary results from the planned interim analysis of the first 11 patients to complete its Phase 2 study of nelotanserin in Lewy body dementia patients. Based on these interim results, Axovant plans to expand patient recruitment in this study and will begin preparations for a Phase 3 registration program expected to start in the second half of 2017.

Click here to read the full release